How Payers Are Reacting to Insulin Price Changes

cafead

Administrator
Staff member
  • cafead   Sep 15, 2023 at 11:42: AM
via Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products. She also discusses MMIT’s research on such glucagon-like peptide 1 (GLP-1) drugs as Ozempic and Mounjaro.

article source
 

<